Skip to main content

Advertisement

SpringerLink
Log in

Management of Meningeal Neoplasms: Meningiomas and Hemangiopericytomas

  • CNS Malignancies
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Meningiomas are the most frequently diagnosed primary brain tumor accounting for nearly one third of all primary brain and central nervous system tumors reported in the United States. According to the 2007 World Health Organization classification scheme, Grade I meningiomas are benign, Grade II defines atypical lesions, while Grade III meningiomas are anaplastic or frankly malignant tumors. Not surprisingly, Grade II and III meningiomas usually follow a more aggressive course and confer a worse prognosis. The diagnosis of meningioma is confirmed by pathologic examination and improvements in imaging help to better define when observation versus intervention is appropriate. Surgical resection, when possible, is the mainstay of treatment. When complete resection is not possible, stereotactic radiosurgery (SRS) can result in disease stabilization. Chemotherapy has yet to result in reproducible long-term disease free or overall survival benefits. Biologic agents remain under investigation. Hemangiopericytomas are rare dural based sarcomas. These tumors are known for their aggressiveness, high recurrence rates and their proclivity to metastasize to extracranial locations. Gross total resection when feasible remains the treatment of choice.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Perry A, Louis DN, Scheithauer BW, Budka H, von Meningiomas DA. In: Louis D, Ohgaki H, Wiestler O, Webster C, editors. WHO classification of tumours of the central nervous system. 4th ed. France: International Agency for Research on Cancer; 2007. p. 164–80.

    Google Scholar 

  2. Park J, Black P. Primary meningeal neoplasms. Principles of neuro-oncology. In: Schiff D, Oneil P, editors. United States: McGraw-Hill; 2005. p. 371–77.

  3. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neuro Oncol. 2010;99:379–91.

    Article  CAS  Google Scholar 

  4. Durand A, Labrousse F, Jouvet A, Bauchet L, Kalamaridès M, Menei P, et al. WHO grade II and III meningiomas: a study of prognostic factors. J Neurooncol. 2009;95(3):367–75.

    Article  PubMed  Google Scholar 

  5. Saloner D, Uzelac A, Hetts S, Martin A, Dillon W. Modern meningioma imaging techniques. J Neurooncol. 2010;99(3):333–40.

    Article  PubMed  CAS  Google Scholar 

  6. Lee J, Kang K, Park S, Lee S, Paeng J, et al. 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1574–82.

    Article  PubMed  Google Scholar 

  7. Nathoo N, Ugokwe K, Chang AS, Li L, Ross J, Suh JH, et al. The role of 111indium-octreotide brain scintigraphy in the diagnosis of cranial, dural-based meningiomas. J Neurooncol. 2007;81(2):167–74.

    Article  PubMed  Google Scholar 

  8. Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113(5):1036–42. This study highlights the importance of observation during the course of treatment for small asymptomatic meningiomas, particularly those with an initial diameter < 2 cm.

    Article  PubMed  Google Scholar 

  9. Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957;20(1):22–39.

    Google Scholar 

  10. Sughrue ME, Kane AJ, Shangari G, Rutkowski MJ, McDermott MW, Berger MS, et al. The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas. J Neurosurg. 2010;113(5):1026–7. This study investigated the relevance of aggressive surgical techniques in the treatment of Grade I meningiomas and found that the benefit of more aggressive attempts to resect the tumor with dura and underlying bone was negligible compared with more conservative surgical measures.

    Article  Google Scholar 

  11. Sughrue ME, Sanai N, Shangari G, Parsa AT, Berger MS, McDermott MW. Outcome and survival following primary and repeat surgery for World Health Organization Grade III meningiomas. J Neurosurg. 2010;113:202–9.

    Article  PubMed  Google Scholar 

  12. Mendenhall WM, Morris CG, Amdur RJ, Foote KD, Friedman WA. Radiotherapy alone or after subtotal resection for benign skull base meningiomas. Cancer. 2003;98:1473–82.

    Article  PubMed  Google Scholar 

  13. Minnitti G, Amichetti M, Enrici RM. Radiotherapy and radiosurgery for benign skull base meningiomas. Radiot Oncol. 2009;14(4):42.

    Article  Google Scholar 

  14. Pannullo SC, Fraser JF, Moliterno J, Cobb W, Stieg PE. Stereotactic radiosurgery: A meta-analysis of current therapeutic applications in neuro-oncologic disease. J Neurooncol. 2010; Epub ahead of print

  15. Leães CGS, Meurer RT, Coutinho LB, Ferreira N, et al. Immunohistochemical expression of aromatase and estrogen, androgen and progesterone receptors in normal and neoplastic human meningeal cells. Neuropathology. 2010;30:44–9.

    Article  PubMed  Google Scholar 

  16. Goodwin J, Crowley J, Eyre H, Stafford B, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75–7.

    Article  PubMed  CAS  Google Scholar 

  17. Grunberg S, Weiss M, Russell C, Spitz I, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Investigation. 2006;24(8):727–33.

    Article  PubMed  CAS  Google Scholar 

  18. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–73.

    Article  PubMed  CAS  Google Scholar 

  19. Schrell UM, Rittig MG, Anders M, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. I. Inhibition of primary human meningioma cells in culture and in meningioma transplants by induction of the apoptotic pathway. J Neurosurg. 1997;86(5):845–52.

    Article  PubMed  CAS  Google Scholar 

  20. Schrell UM, Rittig MG, Anders M, Koch UH, Marschalek R, Kiesewetter F, et al. Hydroxyurea for treatment of unresectable and recurrent meningiomas. II. Decrease in the size of meningiomas in patients treated with hydroxyurea. J Neurosurg. 1997;86(5):840–4.

    Article  PubMed  CAS  Google Scholar 

  21. Fuentes S, Chinot O, Dufour H, Paz-Paredes A, Métellus P, Barrie-Attarian M, et al. Hydroxyurea treatment for unresectable meningioma. Neurochirurgie. 2004;50(4):461–7.

    Article  PubMed  CAS  Google Scholar 

  22. Loven D, Hardoff R, Sever ZB, Steinmetz AP, et al. Non-resectable slow-growing meningiomas treated by hydroxyurea. J Neurooncol. 2004;67:221–6.

    Article  PubMed  Google Scholar 

  23. Mason WP, Gentill F, Macdonald DR, Hariharan S, et al. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg 2002;97:341–346, 200

    Google Scholar 

  24. Newton HB. Hydroxyurea chemotherapy in the treatment of meningiomas. Neurosurg Focus. 2007;23(4):E11.

    Article  PubMed  Google Scholar 

  25. Newton HB, Scott SR, Volpi C. Hydroxyurea chemotherapy for meningiomas: enlarged cohort with extended follow-up. Br J Neurosurg. 2004;18(5):495–9.

    Article  PubMed  CAS  Google Scholar 

  26. Rosenthal MA, Ashley DL, Cher L. Treatment of high risk or recurrent meningiomas with hydroxyurea. J Clin Neurosci. 2002;9(2):156–8.

    Article  PubMed  Google Scholar 

  27. Weston GJ, Martin AJ, Mufti GJ, Strong AJ, Gleeson MJ. Hydroxyurea treatment of meningiomas: a pilot study. Skull Base. 2006;16(3):157–60.

    Article  PubMed  Google Scholar 

  28. Gupta V, Su YS, Samuelson CG, Liebes LF, Chamberlain MC. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007;106(3):455–62.

    Article  PubMed  Google Scholar 

  29. Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006;78(3):271–6.

    Article  PubMed  CAS  Google Scholar 

  30. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004;13;62(7):1210–2.

    Google Scholar 

  31. Muhr C, Gudjonsson O, Lilja A, Hartman M, Zhang ZJ, Långström B. Meningioma treated with interferon-alpha, evaluated with [(11)C]-L-methionine positron emission tomography. Clin Cancer Res. 2001;7(8):2269–76.

    PubMed  CAS  Google Scholar 

  32. Chamberlain MC, Glantz MJ. Interferon-α for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008;113(8):2146–51.

    Article  PubMed  CAS  Google Scholar 

  33. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01–08). J Neuro Oncol. 2009;11(6):853–60.

    Article  CAS  Google Scholar 

  34. Norden A, Raizer J, Abrey L, Lamborn K, Wen P, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96:211–7.

    Article  PubMed  CAS  Google Scholar 

  35. Rutkowski MJ, Sughrue ME, Kane AJ, Aranda D, et al. Predictors of mortality following treatment of intracranial hemangiopericytoma. J Neurosurg. 2010;113(2):333–9. This study highlights the importance of gross total resection, and its superior survival advantage as compared to subtotal resection and post-operative radiation in patients with hemangiopericytomas.

    Article  PubMed  Google Scholar 

  36. Kim J, Kim D, Chung H-T, et al. Gamma Knife stereotactic radiosurgery for intracranial hemangiopericytomas. J Neurooncol. 2010;99:115–22.

    Article  PubMed  Google Scholar 

  37. Soyuer S, Chang EL, Selek U, McCutcheon IE, Maor MH. Intracranial meningeal hemangiopericytoma: the role of radiotherapy. Cancer. 2004;100:1491–7.

    Article  PubMed  Google Scholar 

  38. Chamberlain MC, Glantz MJ. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. NEU. 2008;63(4):720–6.

    Google Scholar 

  39. Peters KB, McLendon R, Morse MA, Vredenburgh JJ. Treatment of recurrent intracranial hemangiopericytoma with SRC-related tyrosine kinase targeted therapy: a case report. Case Rep Oncol. 2010;3:93–7.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA

    Zanetta Lamar MD & Glenn J. Lesser MD

Authors
  1. Zanetta Lamar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glenn J. Lesser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zanetta Lamar MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamar, Z., Lesser, G.J. Management of Meningeal Neoplasms: Meningiomas and Hemangiopericytomas. Curr. Treat. Options in Oncol. 12, 230–239 (2011). https://doi.org/10.1007/s11864-011-0156-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0156-2

Keywords

Search

Navigation